Australia: Where Value Beats Cost
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Address: Suite 4, 13B Narabang Way Belrose NSW 2085,Australia
Tel: 1800 800 765
Web: http://www.galderma.com.au/
Since the creation of Galderma in 1981 as a joint venture between Nestlé and L’Oréal, all of Galderma’s resources have been channelled in a single direction: to provide innovative therapeutic, corrective and aesthetic solutions that meet the needs of dermatology patients and physicians.
Galderma’s experience has taught us that the effects of skin conditions reach much deeper than the skin itself. By treating these conditions, Galderma helps people preserve and recover a healthy skin. Galderma pays special attention not only to the safety and efficacy of its products, but also to the way they can be best administrated by the patients themselves or by medical professionals. This constant search for the best therapeutic and aesthetic results drives Galderma scientists to explore new areas in dermatological innovation.
Galderma’s growing portfolio includes treatment for major skin conditions – acne, pigmentary disorders, skin cancers, rosacea, psoriasis / SRD (Steroid-Responsive Dermatoses), onychomycosis and skin senescence.
Dermatology
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
See our Cookie Privacy Policy Here
